

EMERGING CONCEPTS IN THE RECOGNITION AND MANAGEMENT OF SLE



RESOURCES

Society Guidelines

Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. *Arthritis Care Res* (Hoboken). 2012;64(6):797-808.

Tedeschi SK, Johnson SR, Boumpas D, et al. Developing and refining new candidate criteria for systemic lupus erythematosus classification: An international collaboration. *Arthritis Care Res* (Hoboken). 2018;70(4):571-81.

Aringer M, Costenbader KH, Brinks R, et al. OP0020 Validation of new systemic lupus erythematosus classification criteria. *Ann Rheum Dis*. 2018;77:60. Available at https://ard.bmj.com/content/annrheumdis/77/Suppl_2/60.2.full.pdf

LLDAS

Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a lupus low disease activity state (LLDAS). *Ann Rheum Dis*. 2016;75(9):1615-21.

Petri M, Magder LS. Comparison of remission and lupus low disease activity state in damage prevention in a United States systemic lupus erythematosus cohort. *Arthritis Rheumatol*. 2018;70(11):1790-5.

Hydroxychloroquine

Marmor MF, Kellner U, Lai TY, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). *Ophthalmology*. 2016;123(6):1386-94.

Rempenault C, Combe B, Barnetche T, et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. *Ann Rheum Dis*. 2018;77(1):98-103.

Pakchotanon R, Gladman DD, Su J, Urowitz MB. More consistent antimalarial intake in first 5 years of disease is associated with better prognosis in patients with systemic lupus erythematosus. *J Rheumatol*. 2018;45(1):90-4.

Belimumab

Wallace DJ, Ginzler E, Merrill JT, et al. Sustained safety and efficacy over 10 years with belimumab (BEL) plus standard systemic lupus erythematosus (SLE) therapy (SOC) in patients with SLE. *Ann Rheum Dis*. 2017;76(Suppl 2):150. Available at <http://scientific.sparx-ip.net/archiveeular/?c=a&searchfor=wallace&view=4&item=2017OP0232>

Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: A fifty-two-week randomized, double-blind, placebo-controlled study. *Arthritis Rheumatol*. 2017;69(5):1016-27.